Abstract. Luminal hydrogen sulfide (H 2 S), a gasotransmitter, causes colonic pain / referred hyperalgesia in mice, most probably via activation of T-type Ca 2+ channels. Here we analyzed the mechanisms for H 2 S-induced facilitation of colonic pain signals. Intracolonic administration of NaHS, an H 2 S donor, evoked visceral pain−like nociceptive behavior and referred hyperalgesia in mice, an effect abolished by NNC 55-0396, a selective T-type Ca 2+ -channel blocker, or by knockdown of Ca v 3.2. AP18, a TRPA1 blocker, also prevented the NaHS-induced colonic pain and referred hyperalgesia. These findings demonstrate that H 2 S-induced colonic pain and referred hyperalgesia require activation of both Ca v 3.2 and TRPA1 channels in mice.
Hydrogen sulfide (H 2 S), a gasotransmitter, is generated by enzymes such as cystathionine-γ-lyase (CSE) and cystathionine-β-synthase (CBS) from L-cysteine. We have demonstrated that H 2 S facilitates somatic pain signaling through the activation of Ca v 3.2 T-type Ca 2+ channels (1, 2) , and the functional upregulation of the H 2 S/Ca v 3.2 pathway is involved in the neuropathic pain induced by surgical injury to the L5 spinal nerve (3) and repeated administration of paclitaxel (4) . It has been reported that the H 2 S-producing enzyme, CBS, in colonic sensory neurons is upregulated and contributes to visceral hypersensitivity in a rat model of irritable bowel syndrome (5). Interestingly, H 2 S is also capable of causing colonic and pancreatic pain, an effect blocked by mibefradil, a T-type Ca 2+ -channel blocker (6, 7) . However, mibefradil may also inhibit some ion channels, particularly L-type Ca 2+ channels, other than T-type Ca 2+ channels, and hence the involvement of T-type Ca 2+ channels in H 2 S-induced visceral pain has yet to be ascertained using more selective T-type Ca 2+ -channel blockers, if any. It has also yet to be tested if the Ca v 3.2 isoform is involved in the H 2 S-induced visceral pain, as in the somatic pain signaling (2) . Further, the TRPA1 channel, another target for H 2 S (8), in addition to Ca v 3.2, contributes to the H 2 S-induced somatic hyperalgesia/allodynia in mice (9) , whereas the role of TRPA1 in the H 2 S-evoked visceral pain is still open to question. To address those remaining concerns and questions, here we further analyzed the mechanisms for the colonic pain / referred hyperalgesia caused by intracolonic administration of NaHS, a donor of H 2 S, in mice, using NNC 55-0396, a highly selective T-type Ca 2+ -channel blocker, the antisense (AS) oligodeoxynucleotides (ODNs) for silencing of Ca v 3.2, and AP18, a TRPA1 blocker.
Female ddY mice weighing 18 -25 g were purchased from Kiwa Laboratory Animals Co., Ltd. (Wakayama). The animals were housed in a temperature-controlled room under a 12-h day/night cycle at about 24°C and had free access to food and water before the experiments, unless otherwise stated. All experimental protocols were approved by the Committee for the Care and Use of Laboratory Animals at Kinki University and were in accordance with the Guide for the care and use of laboratory animals published by the US National Institutes of Health (NIH Publication No. 85-23, revised 1996). Visceral pain−like nociceptive behavior and referred hyper-algesia in mice were assessed as described previously (10) with minor modifications (6) . Briefly, mice were placed on a raised wire mesh, under a clear plastic box (23.5 × 16.6 × 12.4 cm) and acclimated to the experimental environment for 30 min. Using a cannula with a rounded tip (external diameter: 1.6 mm), NaHS (Kishida Chem. Co., Ltd., Osaka) at 5 nmol/mouse (100 μM solution) or allyl isothiocyanate (AITC; Tokyo Chemical Industry Co., Ltd., Tokyo) at 514 nmol/mouse (10.3 mM solution) in a volume of 50 μL was administered into the colon at 3 cm from the anus in the mice, after application of Vaseline in the perianal area. Immediately after intracolonic (i.col.) administration of NaHS or AITC, visceral pain-related nociceptive behavior such as licking of the abdomen was measured for 30 min. Assessment of referred hyperalgesia was performed 30 min after i.col. administration. To determine referred hyperalgesia, the lower to mid abdomen of the mice was stimulated mechanically with three distinct von Frey filaments with strengths of 0.02, 0.16, and 1.0 g, in the ascending order of their strength, at intervals of 5 -10 s, 10 times for each filament. Scoring of nociceptive behavior was defined as described previously (6) . AITC was dissolved in peanut oil. (8, 9) . A mixture of two types of AS-ODNs for Ca v 3.2 or SC-ODN (No. 1 and 2, 1 μg/μL each) in a volume of 5 μL was administered i.t. repeatedly, once a day for 3 days in mice. Successful silencing of Ca v 3.2 by the AS-ODNs was determined by western blotting of Ca v 3.2 protein in the dorsal root ganglion (DRG) at L1 -L6 levels, as reported previously (9) . Data are represented as means with S.E.M. Statistical significance for parametric data was evaluated by analysis of variance followed by the Tukey test for multiple comparisons. For non-parametric analysis, the Kruskal-Wallis H test followed by a least significant difference (LSD)-type test was employed for multiple comparisons. Significance was set at a level of P < 0.05. NaHS, administered i.col., at 5 nmol/mouse, a submaximal dose (6), induced visceral pain−like behavior (Fig. 1A) and referred hyperalgesia in the abdomen (Fig.  1B) . NNC 55-0396, the highly selective T-type Ca 2+ -channel blocker, when given i.p. at 20 mg/kg, strongly suppressed the NaHS-induced visceral pain−like nociceptive behavior and referred hyperalgesia (Fig. 1: A and  B) , although it alone exhibited no antinociceptive activity in our preliminary experiments. As reported previously (9), repeated i.t. administration of AS-ODNs targeting Ca v 3.2, but not the SC-ODNs, clearly suppressed the protein levels of Ca v 3.2 in the DRG ( Fig. 2A) and pre- vented the NaHS-induced visceral pain-like nociceptive behavior (Fig. 2B ) and referred hyperalgesia in mice (Fig. 2C) . Further, i.p. pretreatment with AP18, a TRPA1 blocker, at 10 mg/kg inhibited the visceral pain−like nociceptive behavior and referred hyperalgesia induced by AITC, a TRPA1 agonist (Fig. 3: B and D) , and by NaHS (Fig. 3: A and C) , although it alone had no significant antinociceptive effect (Fig. 3: B and D) .
Our algesia in rats (2) and mice (8, 9) . These findings are in agreement with the recent evidence that Ca v 3.2, among the three isoforms of T-type Ca 2+ channels, in the sensory neurons plays a major role in processing of somatic (11) and visceral pain (12) . Previously, we have shown that luminal H 2 S-induced colonic pain / referred hyperalgesia is prevented by pretreatment with zinc chloride (ZnCl 2 ) and that luminal zinc chelators mimic the T-type Ca 2+ channel-dependent colonic pain / referred hyperalgesia caused by H 2 S (13). We have thus proposed that H 2 S might interact with endogenous zinc and then sensitize the Ca v 3.2 isoform of T-type Ca 2+ channels, leading to colonic pain / referred hyperalgesia (13), since Ca v 3.2 is much more sensitive to zinc inhibition than the other isoforms, Ca v 3.1 and Ca v 3.3, and that zinc chelators cancel endogenous zinc inhibition of Ca v 3.2 (14) . This hypothesis is strongly supported by the present data. On the other hand, TRPA1 is now considered a target for H 2 S (8). Our latest study has shown that the activation of TRPA1 in addition to Ca v 3.2 is required for the H 2 Sinduced somatic pain (9) . Similarly, the present findings suggest that the H 2 S-induced colonic pain and referred hyperalgesia are also dependent on activation of TRPA1. Although we have no evidence to interpret how Ca v 3.2 and TRPA1, upon activation by H 2 S, cooperate to cause colonic pain, it is likely that the H 2 S-sensitized Ca v 3.2 is greatly activated in responses to membrane depolarization following the H 2 S-induced activation of TRPA1 channels, leading to the induction of colonic pain.
In conclusion, our study implies that H 2 S-induced colonic pain and referred hyperalgesia require activation of both Ca v 3.2 and TRPA1 channels in mice.
